Garadacimab (CSL312)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Garadacimab (CSL312), covering 2026-01-26 to 2026-01-26. Get the full timeline:
Most recent: Clinical Trial Update: Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks [Phase 3]